Keywords: Pluristem, PLX cells, Muscle regeneration, Germany, Ph I/II

Pluristem cleared to start Phase I/II PLX cell study for muscle regeneration in Germany

Article | 08 August 2012

Print This

In a second piece of good news this week, Israeli biotech company Pluristem Therapeutics (TASE: PLTR) revealed that it has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in